Marker Therapeutics Inc (MRKR)

[Phantom Lord]

Below is copied from one of my previous posts HERE. That post was also an update on a prior post which you can link back to for clickable links to all of Marker's trials.

This is not all of the info that could be coming. I remember reading somewhere they might have some data Q1 but not 100% on where I heard that.


Q1 2019:

This is looking pretty bare from what I am seeing. Maybe a good time to add to positions if the SP dips due to lack of news barring any surprises.

Q2 2019:

1. Interim data from Tapimmune sponsored trial of TPIV 200 in patients w/ Ovarian cancer. I believe this was pushed back.
2. Completion of TPIV200 & Durvalumab combo trial w/ $AZN in patients w/ ovarian cancer.
3. Primary completion of ADSPAM trial in AML.
4. Primary completion of TACTAM trial in multiple myeloma.
5. Primary completion of STELLA trial in acute lymphoblastic leukemia.

2H 2019:

I’ve lumped Q3 & Q4 together as I’m going to speculate a bit since there aren’t a lot of set dates in this timeframe. Given all the completion dates in Q2 we could hear more information as to the next trials, i.e. PII & PIII trials. With the primary completion of ADSPAM, TACTAM, & STELLA I would not be surprised to see our participation at ASH. This usually takes place in the beginning of December. For those that don’t know this is a MAJOR conference, think ASCO. Obviously, speculation but I know the company is hoping to have a presentation accepted.


All trials referenced above, along with the rest of Tapimmune’s (Marker’s) trials, are below. Since I copied and pasted these aren't links but in the original post, linked at the top of this post, I've linked everything below to clinicaltrials.gov.


ADSPAM – AML: NCT02494167

TACTAL – Leukemia: NCT01333046

TACTAM – Multiple Myeloma: NCT02291848

TACTIC – Breast Cancer: NCT03093350

TACTOPS – Pancreatic Cancer: NCT03192462

STELLA – Acute Lymphoblastic Leukemia: NCT02475707

TPIV 200 for ovarian: NCT02978222

TPIV 200 for TNBC: NCT02593227

Combination trial of TPIV 200 & Durvalumab for ovarian: NCT02764333

TPIV 200 for TNBC funded by DOD w/ Mayo Clinic: NCT03012100

Good Luck everyone!